Phase II Trial of Continuation Therapy in Advanced NSCLC

Status Completed

Clinical Trial Summary

This is a single-arm phase II study of continuation immunotherapy with pembrolizumab following initial benefit (CR, PR, or SD ≥ 3 months) with a PD-1 or PD-L1 inhibitor.

Clinical Trial Description

OUTLINE: This is a multi-center study. Patients who have been treated with a PD-1 or PD-L1 inhibitor and experienced a PFS of ≥3 months will be enrolled within 6 weeks of last dose of PD-1 or PD-L1 inhibitor. On Day 1 of each 3-week cycle, subjects will first receive pembrolizumab at a dose of 200mg IV every three weeks in combination with chemotherapy. Partner chemotherapy will be either gemcitabine 1000mg/m2 IV D1 and D8 every three weeks, docetaxel 75mg/m2 IV D1 every three weeks, or pemetrexed 500mg/m2 IV D1 every 3 weeks (pemetrexed for non-squamous histologies only). Subjects will continue to receive this combination until progression or intolerable toxicity. Administration Sequence: First Sequence - Pembrolizumab 200mg IV on Day 1 (cycle = 21 days) Administration Sequence: Second Sequence - Gemcitabine 1000mg/m^2 IV on Days 1,8 (cycle = 21 days) - Docetaxel 75mg/^2 IV on Days 1,8 (cycle = 21 days) - Pemetrexed 500mg/m^2 IV on Day 1 (cycle -= 21 days) ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03083808
Study type	Interventional
Source	Big Ten Cancer Research Consortium
Contact
Status	Completed
Phase	Phase 2
Start date	March 20, 2017
Completion date	March 3, 2022

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02495233` - A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)	Phase 1/Phase 2
Withdrawn	`NCT02672358` - Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC	Phase 2
Recruiting	`NCT05815472` - Advanced Patient Monitoring and A.I. Supported Outcomes Assessment in Lung Cancer Using Internet of Things Technologies (A.I. - APALITT)	N/A
Not yet recruiting	`NCT05900219` - Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study	Phase 2
Not yet recruiting	`NCT04560244` - A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment	Phase 2
Not yet recruiting	`NCT02907606` - Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study	N/A
Completed	`NCT01924416` - Lung Cancer Information Study (LCIS-R01)	N/A
Completed	`NCT01136083` - Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients	N/A
Completed	`NCT00831454` - Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection	N/A
Completed	`NCT00363766` - Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer	Phase 2
Completed	`NCT00913705` - Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer	Phase 3
Completed	`NCT01124864` - A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.	Phase 2
Completed	`NCT01383135` - Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2	Early Phase 1
Completed	`NCT00049998` - Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer	Phase 3
Terminated	`NCT05061537` - Study of PF-07263689 in Participants With Selected Advanced Solid Tumors	Phase 1
Completed	`NCT03320044` - Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing
Recruiting	`NCT04895930` - Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC	Phase 2
Recruiting	`NCT03267654` - Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance	Phase 2
Recruiting	`NCT04401059` - Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study	Phase 4
Completed	`NCT02965391` - Dynamic Changes of Circulating Tumor DNA in Surgical Lung Cancer Patients